{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T15:48:56Z","timestamp":1772293736768,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.gastrohep.2016.01.011","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T22:04:54Z","timestamp":1458079494000},"page":"117-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Enfermedad inflamatoria intestinal como efecto parad\u00f3jico del tratamiento con anti-TNF-\u03b1"],"prefix":"10.1016","volume":"40","author":[{"given":"Ainara","family":"Iriarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Zaera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bachiller-Corral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"L\u00f3pez-Sanrom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2016.01.011_bib0115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semarthrit.2008.06.004","article-title":"Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action","volume":"39","author":"Haraoui","year":"2009","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0120","first-page":"72","article-title":"Tumor necrosis factors blocking agents: Analogies and differences","volume":"83","author":"Benucci","year":"2012","journal-title":"Acta Biomed."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0125","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1084\/jem.20091233","article-title":"Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease","volume":"206","author":"Smith","year":"2009","journal-title":"J Exp Med."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0130","first-page":"752","article-title":"Development of Crohn's disease in a patient taking etanercept","volume":"32","author":"Oh","year":"2005","journal-title":"J Rheumatol."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0135","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: A retrospective study","volume":"48","author":"Fouache","year":"2009","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0140","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/rheumatology\/keq136","article-title":"Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: A French retrospective study","volume":"49","author":"Dallocchio","year":"2010","journal-title":"Rheumatology (Oxford)."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0150","first-page":"342","article-title":"Emergence of Crohn's disease in juvenile idiopathic arthritis during treatment with etanercept: A causal link or a mere coincidence?","volume":"19","author":"Oikonomou","year":"2010","journal-title":"J Gastrointestin Liver Dis."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0155","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s10620-014-3147-x","article-title":"Colitis associated with biological agents","volume":"59","author":"Khirfan","year":"2014","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: A nationwide series","volume":"79","author":"Toussirot","year":"2012","journal-title":"Joint Bone Spine."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0165","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0170","first-page":"532","article-title":"New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept","volume":"35","author":"Song","year":"2008","journal-title":"J Rheumatol."},{"issue":"Suppl A","key":"10.1016\/j.gastrohep.2016.01.011_bib0175","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0180","first-page":"86","article-title":"Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice","volume":"46","author":"Georgopoulos","year":"1996","journal-title":"J Inflamm."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0185","unstructured":"Agency EM. Etanercept-Enbrel Product information [updated 24\/02\/2015. Disponible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf"},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0190","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0195","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/MJT.0b013e31825e6089","article-title":"Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: A case report with a review of literature","volume":"21","author":"Bawany","year":"2014","journal-title":"Am J Ther."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0200","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.30546","article-title":"Induction of inflammatory bowel disease flares by golimumab: Report of three patients with enteropathic spondylarthritis or ankylosing spondylitis and comorbid colitis","volume":"63","author":"Fiehn","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/00365521.2012.733956","article-title":"Crohn's disease diagnosis during adalimumab treatment","volume":"48","author":"Fernandez Salazar","year":"2013","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0210","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1185\/030079906X104641","article-title":"Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: An exploration using US healthcare claims data, 2001-2002","volume":"22","author":"Robinson","year":"2006","journal-title":"Curr Med Res Opin."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.reuma.2015.01.002","article-title":"Two-year incidence of psoriasis, uveitis and inflammatory bowel disease in patients with spondyloarthritis: A study in the AQUILES cohort","volume":"12","author":"Garc\u00eda-Vicu\u00f1a","year":"2015","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.gastrohep.2016.01.011_bib0220","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.3899\/jrheum.140472","article-title":"Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics","volume":"42","author":"Barthel","year":"2015","journal-title":"J Rheumatol."}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570516000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570516000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T09:21:26Z","timestamp":1536916886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570516000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0210570516000881"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2016.01.011","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfermedad inflamatoria intestinal como efecto parad\u00f3jico del tratamiento con anti-TNF-\u03b1","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2016.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U., AEEH y AEG. All rights reserved.","name":"copyright","label":"Copyright"}]}}